Zepbound (tirzepatide) tracker
Educational reference for Zepbound (tirzepatide). Use it inside TrackPep to log doses, side effects, and rotation sites.
Half-life
120 h
Tmax
24 h
Category
glp1
> PLACEHOLDER — pending clinical review by licensed pharmacist. Zepbound is Eli Lilly's brand of tirzepatide for chronic weight management.
Mechanism
Zepbound is a brand name for tirzepatide, a dual GIP and GLP-1 receptor agonist, at doses used for weight management. See the tirzepatide entry for the full mechanism.
Research summary
Zepbound is the tirzepatide product approved for chronic weight management (SURMOUNT program). See the tirzepatide entry for broader context.
Dosing in the literature
Regimens are individualized and set by a prescribing clinician; they are outside the scope of this summary. See the tirzepatide entry.
Reported side effects
As a tirzepatide product, gastrointestinal effects are most commonly reported; prescribing information includes class warnings. See the tirzepatide entry. This is not a complete safety profile.
Stacking notes
See the tirzepatide entry. Combination with other agents is a clinical decision.
Educational summary of published research. Not dosing guidance or medical advice.
Sources
- Zepbound prescribing information · FDA prescribing information (2023)available via DailyMed; see tirzepatide entry
References
Track Zepbound (tirzepatide) in TrackPep
Reconstitution calculator, interactive body-map rotation, side-effect timeline, weight trends, and a private log — all in one place. Free to try.